affiliate disclosure · We earn affiliate commission on some vendor links. Audits, scores, and rankings are independent — vendors do not pay for placement and do not see drafts. read more →
BPC-157 and TB-500 are the most-stacked combination in research-peptide protocols. The compounds work through different mechanisms — angiogenesis vs actin sequestration — which is why the combination is studied. Here's the literature read.
BPC-157 and TB-500 are the two most-cited research peptides for tissue repair and recovery protocols, and they appear together in vendor catalogs more often than any other healing-peptide pair. The 200-test Janoshik public-tests corpus shows BPC-157 + TB-500 blends as the most-tested non-GLP-1 compound category in the public dataset (10 publicly-submitted blend tests).
The reason for the pairing isn't faddish — it's mechanistic. The two compounds work through structurally different pathways. The combination is studied because the pathways are complementary, not redundant.
BPC-157 is a 15-amino-acid sequence derived from a protein found in human gastric juice. The published preclinical mechanism centers on:
The preclinical literature spans gastrointestinal injury, tendon and ligament repair, central-nervous-system protection, and cardiovascular protection. The breadth of mechanisms is what makes BPC-157 a proof-of-concept compound for cytoprotective research.
TB-500 (thymosin beta-4 fragment) is a 4-amino-acid sequence (the LKKTETQ active fragment of thymosin beta-4). The mechanism is structurally different:
The actin-binding mechanism is unusual among research peptides. Most research peptides act through receptor binding or enzyme inhibition; TB-500 acts through direct cytoskeletal modulation.
The two compounds operate at different stages of the tissue-repair cascade:
| Stage | BPC-157 contribution | TB-500 contribution | |---|---|---| | Initial injury response | Cytoprotection, anti-inflammatory | Inflammation modulation | | Vasculogenesis | Strong angiogenesis driver | Endothelial cell migration | | Cell migration | Indirect (via signaling) | Direct (via actin sequestration) | | Matrix remodeling | Collagen and growth-factor effects | Fibroblast migration to site | | Long-term recovery | Receptor-pathway maintenance | Cytoskeletal regeneration |
The non-redundancy is the structural reason research protocols combine them. BPC-157 supports the vascular and signaling layer of tissue repair; TB-500 supports the cellular migration and cytoskeletal layer. Different mechanisms, same overall recovery process.
The combination dosing in the published research is typically separate administrations of each compound at independently-published reference doses, not a co-formulated blend.
For BPC-157, the most-cited research doses are 250 mcg/day or 500 mcg/day (see our BPC-157 dosage calculator for body-weight scaling).
For TB-500, the published research-protocol literature uses higher absolute mg-doses than BPC-157 — typical reference figures are 2 mg to 5 mg administered weekly, with loading-phase protocols often citing 2 mg twice-weekly for the first 4–6 weeks then dropping to maintenance.
The combination protocols in the published literature do not co-formulate. They schedule the compounds independently, citing different pharmacokinetics:
The vendor-catalog "blend" products that combine both compounds in a single vial are a manufacturing convenience, not a published-protocol practice.
In our 200-test Janoshik public-tests mirror, the BPC-157 + TB-500 blend category appears 10 times. The pattern across those tests:
The blend format trades single-compound purity precision for the convenience of a single reconstitution. Whether that trade is worth making depends on the buyer's research-protocol precision needs.
Three claims commonly made about the BPC-157 + TB-500 combination that are not supported by published research:
Synergy effects beyond additive. The published preclinical literature studies the compounds independently at well-characterized doses. Studies that test combination dosing and compare to additive expectations are limited. Anecdotal reports of "synergy" beyond the sum of independent effects are not currently in the published data.
Specific recovery-time reductions. Research-protocol literature characterizes mechanism, not aggregate human-recovery time. Vendor marketing claims of "X% faster recovery" or "cuts recovery time by Y days" are not supported by published Phase 2+ trial data — there is no Phase 2+ trial data.
Dose equivalence between compounds. BPC-157 doses cluster in mcg ranges (250–500 mcg/day); TB-500 doses cluster in mg ranges (2–5 mg weekly). The compounds are not interchangeable on a unit basis. Vendor marketing that conflates the dose ranges is misreading the literature.
Neither BPC-157 nor TB-500 is FDA-approved for any human indication. The published research is preclinical (rodent and in vitro studies) and limited human research-protocol data. Both compounds appear in research-peptide vendor catalogs; neither is in a brand-prescription or 503A-compounding pathway.
The September 2025 FDA Warning Letter sweep documented in our FDA peptide enforcement timeline named several vendors specifically for drug claims on BPC-157 and TB-500 marketing pages — claims like "treats injuries" or "speeds recovery" without research-only labeling. The compounds are research-grade; vendor marketing language that crosses into clinical claims attracts regulatory action regardless of the compound's underlying research literature.
This article describes mechanisms and research-protocol literature. It does not address:
New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.